Natco

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing.

Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patients with mild COVID-19.

Taiho alleged that the Indian drug maker's proposed generic Lonsurf (trifluridine and tipiracil) will infringe the patent

The Delhi High Court on Wednesday allowed Indian drug manufacturers Natco Pharma and Alembic Pharmaceuticals to export Sorafinat and Rivaroxiban, generics of German pharma major Bayer's own cancer and blood thinning medicines. Bayer had initiated proceedings against the two Indian pharma companies to stop them from exporting the drug, which the defendants had claimed were being exported for purposes of experimentation and generation of valuable clinical trial data. Bayer had opposed this stance and argued that such exports did not meet the exceptions to patent infringement provided under Section 107A of the Indian Patents Act, 1970, as they violated conditions of compulsory licenses (Natco) and exceeded reasonable quantities (Alembic). Bayer had claimed that under the compulsory license provided to Natco, the company could only sell Sorafinat within India and that Alembic could not take benefit of the exception as they had exported over 90 kilograms of Rivaroxiban, worth around Rs 3 .